Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

Shots:

• Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim
• The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases
• GPCRs are receptors present in CNS, activates by binding with stimulus or ligand and regulates the functions of brain

Click here to read full press release/ article | Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim